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Abstract
Cholinergic control of the heart is exerted by two distinct branches; the autonomic component represented by the
parasympathetic nervous system, and the recently described non-neuronal cardiomyocyte cholinergic machinery. Previous
evidence has shown that reduced cholinergic function leads to deleterious effects on the myocardium. Yet, whether
conditions of increased cholinergic signaling can offset the pathological remodeling induced by sympathetic hyperactivity,
and its consequences for these two cholinergic axes are unknown. Here, we investigated two models of sympathetic
hyperactivity: i) the chronic beta-adrenergic receptor stimulation evoked by isoproterenol (ISO), and ii) the a2A/a2C-
adrenergic receptor knockout (KO) mice that lack pre-synaptic adrenergic receptors. In both models, cholinergic signaling
was increased by administration of the cholinesterase inhibitor, pyridostigmine. First, we observed that isoproterenol
produces an autonomic imbalance characterized by increased sympathetic and reduced parasympathetic tone. Under this
condition transcripts for cholinergic proteins were upregulated in ventricular myocytes, indicating that non-neuronal
cholinergic machinery is activated during adrenergic overdrive. Pyridostigmine treatment prevented the effects of ISO on
autonomic function and on the ventricular cholinergic machinery, and inhibited cardiac remodeling. a2A/a2C-KO mice
presented reduced ventricular contraction when compared to wild-type mice, and this dysfunction was also reversed by
cholinesterase inhibition. Thus, the cardiac parasympathetic system and non-neuronal cardiomyocyte cholinergic machinery
are modulated in opposite directions under conditions of increased sympathetic drive or ACh availability. Moreover, our
data support the idea that pyridostigmine by restoring ACh availability is beneficial in heart disease.
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Introduction
A substantial amount of data suggests that sympathetic
regulation of heart function, via adrenergic receptors, contributes
to cardiac remodeling and provides a major pathway for
intervention in heart failure (HF) [1], [2], [3]. In contrast, the
precise mechanisms required for long-term cholinergic regulation
of heart function are only now started to be dissected.
Acetylcholine (ACh) is synthesized in the cytoplasm by choline
acetyltransferase (ChAT) and stored within vesicles for release.
Activity-coupled transport of ACh to synaptic vesicles in nerve-
endings is mediated by the vesicular ACh transporter (VAChT)
[4], [5]. All ACh released is degraded by cholinesterases mainly,
acetylcholinesterase (AChE), to form choline and acetate. Choline
is then transported into the cell by the high affinity choline-
transporter (CHT1). Cardiac regulation by the parasympathetic
nervous system is mediated primarily by ACh binding to the M2
muscarinic ACh receptor (M2-AChR). Previous studies demon-
strated that M2-AChR knockout (KO) mice exhibited increased
susceptibility to cardiac stress [6], suggesting a protective role for
the parasympathetic nervous system in the heart. In line with this
finding, vagal stimulation has been shown to be of benefit in heart
failure [7]. Mice with reduced expression of the VAChT (VAChT
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knockdown homozygous mice, VAChT KDHOM mice) [5] have
been generated and were pivotal in demonstrating a role for
VAChT in sustaining cholinergic tone in vivo. These mutant mice
express only 30% of the normal level of VAChT, and present a
number of cholinergic deficits. Our previous publication has
shown that chronic decrease of cholinergic tone in VAChT
KDHOM mice evoked significant cardiac remodeling characterized
by depressed contractile function, calcium (Ca2+) signaling
dysfunction and altered gene expression in cardiomyocytes [8].
Importantly, these changes were reversed by chronic administra-
tion of pyridostigmine, a cholinesterase inhibitor, indicating an
important relationship between ACh availability and proper heart
function. Altogether, these results support the broad theme that
reduced cholinergic function can lead to deleterious effects on the
myocardium, and support the notion that increased parasympa-
thetic tone can exert protective effects. In fact, infusion with the
cholinesterase inhibitor, neostigmine or with a muscarine receptor
agonist, pilocarpine significantly reduced cardiac hypertrophy,
reduced TNF alpha levels, elevated interleukin-10 in heart tissues,
and improved ventricular function in rats with transverse aortic
constriction [9]. Similar cardioprotective effects were observed
when another cholinesterase inhibitor, donepezil, was adminis-
tered to a rat model of myocardial infarction [10] and to a murine
model of volume-overloaded congestive heart failure [11]. In
addition, previous data from Kanazawa et al. [12] have provided
evidence that cholinergic transdifferentiation of sympathetic
neurons takes place during heart failure and this plays a protective
role in the pathogenesis of heart disease. Finally, recent
epidemiological data indicate that the use of cholinesterase
inhibitors in Alzheimer’s disease associates with 34% reduced risk
of myocardial infarction and death [13].
Recently, an intrinsic cardiomyocyte cholinergic system has
been described [14], [15], [16] supporting the assumption of local
ACh release by ventricular myocytes in the heart. Our group has
investigated the importance of this local cholinergic machinery,
and presented evidence that ACh released by cardiomyocytes is
capable of offsetting the deleterious effects of hyperadrenergic
stimulation in vitro [16]. In addition, removal of VAChT or ChAT
exclusively from cardiomyocytes leads to increased levels of
oxidative stress and cardiac hypertrophy [17]. Thus, these data
bring into perspective another level of cholinergic control of
cardiac function that goes beyond the cardiac parasympathetic
system, and it is intrinsic to ventricular myocytes. Yet, whether this
machinery is regulated in vivo, and its relationship with parasym-
pathetic activity is unknown.
In this study, our goal was twofold: (i) to assess the consequences
of increased adrenergic and cholinergic signaling for the heart and
its influence on autonomic function and in the expression levels of
cholinergic and adrenergic components in ventricular myocytes,
and (ii) to investigate whether activation of cholinergic signaling is
capable of offsetting the deleterious effects of increased sympa-
thetic drive in vivo. Here, we show that upregulation of non-
neuronal cholinergic machinery in the heart is observed under
conditions of increased sympathetic drive and reduced parasym-
pathetic tone. When ACh availability is increased by pyridostig-
mine administration cardiac pathological remodeling is prevented
and ventricular function is restored in two animal models of
sympathetic hyperactivity. Thus, our data indicate that cholinergic
signaling might be an important target in heart failure.
Methods
Animal models and drug administration
34 Male Wistar rats (250 g) were used in this study. Cardiac
hypertrophy was induced by daily intraperitoneal injection of (6)
isoproterenol hydrochloride for seven days (4.5 mg/kg body
weight) to rats [18]. Isoproterenol was used as a non-specific b-
adrenergic agonist (ISO; Sigma, St. Louis, MO, USA). Two
distinct doses of Pyridostigmine bromide (0.2 mg/kg body weight
or 0.5 mg/kg body weight) were used in this study. The drug was
administered twice daily by intraperitoneal injection and treat-
ment started concomitantly with ISO injection. Another group of
rats received pyridostigmine alone (0.5 mg/kg body weight).
Control animals were saline-injected.
A cohort of 10 male wild-type (control WT group) and 26
congenic a2A/a2C-adrenergic receptor knockout (KO) mice in a
C57BL6/J genetic background were studied from 5 to 7 months of
age. At this age, these mice display advanced stage cardiomyop-
athy as previously described [19]. a2A/a2C-KO mice were
randomly assigned to receive daily pyridostigmine (3 mg/kg/day)
for 28 days. Pyridostigmine was delivered via subcutaneously
implanted osmotic mini-pumps.
Ethics statement
Animals were maintained at the Universidade Federal de Minas
Gerais (UFMG), Brazil. This study was approved by the
Institutional Animal Care and Use Committee at Universidade
Federal de Minas Gerais.
Vagal and sympathetic function evaluation
The autonomic function and the intrinsic heart rate were
evaluated by autonomic blockade using intravenous injections of
methylatropine (3 mg/Kg, Sigma) or propranolol (4 mg/Kg,
Sigma) at a maximal volume of 0.2 ml per injection after
20 min of baseline conditions. The experiments were performed
in two consecutive days. On the first day, methylatropine was the
first drug injected and after 15 min propranolol injection was
performed. In the second day, to obtain the reverse sequence of
the blockade, propranolol was the first drug administered. After
15 min, methylatropine was injected intravenously. The intrinsic
HR was evaluated after the injection of methylatropine and
propranolol. Using the maximum change of each drug, the
sympathetic tone was calculated, on the first day, as the difference
between the tachycardia evoked by methylatropine and the
intrinsic HR. In the second day, the vagal tone was calculated
as the difference between the intrinsic HR and the bradycardic
response induced by propranolol [20], [21].
Echocardiography
Animals were anaesthetized using a nose cone with isoflurane at
5% for one minute and the maintenance dose was 1.25%. The
anterior chest was shaved, and the animals were placed in supine
position on an imaging stage equipped with built-in electrocar-
diographic electrodes for continuous heart rate monitoring and a
proper heating pad to avoid hypothermia. In vivo cardiac function
was assessed noninvasively using a high-frequency, high-resolution
echocardiographic system consisting of a VEVO 2100 ultrasound
machine equipped with a 30–40 MHz bifrequencial transducer
(Visual Sonics, Toronto, Canada). High-resolution images were
obtained as previously described [22], [23], [24].
Langendorff-perfused hearts
Briefly, after removal the hearts were perfused with a Krebs-
Ringer solution, which was delivered at 37uC in the presence of
Cholinergic Regulation of the Heart
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continuous gassing with 5% CO2 to yield a physiological pH of
7.4. Hearts were perfused with this solution for 50 min, as
previously described [25], [26].
Cardiomyocyte isolation and Ca2+ recording
Adult ventricular myocytes were freshly isolated and stored in
DMEM media (Sigma), until they were used (within 4 h), as
previously described [27]. Intracellular Ca2+ (Ca2+i) imaging
experiments were performed in Fluo-4 AM (6 mmol/L; Invitrogen,
Eugene, OR) loaded-cardiomyocytes for 25 min which were
subsequently washed with an extracellular solution that contained
1.8 mmol/L Ca2+ to remove the excess dye. Cells were electrically
stimulated at 1 Hz to produce steady-state conditions. The
confocal line-scan imaging was performed by a Zeiss LSM
510META confocal microscope. For isoproterenol response
cardiomyocytes were perfused with Normal Tyrode control
solution (in mmol/L, solution 1): NaCl (140), KCl (4), MgCl2
(1), CaCl2 (1.8), Glucose (10), and HEPES (5); pH=7.4 adjusted
with NaOH. Ca2+ transients were first recorded in cardiomyocytes
superfused with solution 1, followed by isoproterenol stimulation
of cells produced by the addition of 50 nmol/L isoproterenol to
solution 1. The myocytes were field-stimulated at 1 Hz and the
data plotted as the percentage increase in Ca2+ transient
fluorescence in the presence of isoproterenol relative to the Ca2+
transient obtained in non-stimulated cells.
Neonatal rat cardiomyocyte culture
Neonatal rat cardiomyocytes were cultured as previously
described [28]. Briefly, cardiac cells were plated in dishes
containing M199 medium supplemented with 100 units/mL
penicillin, 100 mg/mL streptomycin, 10% Fetal Bovine Serum and
2 mmol/L L-glutamine. To prevent growth of fibroblasts, medium
was supplemented with 20 mg/mL cytosine-D-arabinofuranoside
(ARA-c) for 48 hours. For siRNA studies, neonatal cardiomyocyte
cultures at day 4 were transfected with 100 nM of siRNA. The
cells were incubated at 37uC in an atmosphere of 5% CO2 for
30 h and then exposed to isoproterenol (10 mmol/L) for another
24 h prior to use. The cells were then used for qPCR analyses.
The siRNA for AChE was prepared as previously described [16].
Quantitative real time PCR
For RNA purifications, tissues were grounded in a potter and
pestle with liquid nitrogen and total RNA was extracted using
TRIzolH (Invitrogen). For quantitative PCR (qPCR), total RNA
was treated with DNase I (Ambion, Austin, TX, USA) and first
strand cDNA was synthesized using High Capacity cDNA
Transcription Kit (Applied Biosystems, CA, USA) according to
the manufacturer’s instructions. After reverse transcription, the
cDNA was subjected to qPCR on a 7500 Real Time PCR System
(Applied Biosystems, CA, USA) using Power SYBR Green PCR
Master Mix (Applied Biosystems, CA, USA), as previously
described [8].
Cardiac morphometry
Heart hypertrophy was evaluated by morphometry (n = 5 per
group). The rats were anesthetized with 10% ketamine/2%
xylazine (4:3, 0.1 mL/100 g, i.p.) and heart beat was stopped in
diastole using 10% KCl (i.v.). Hearts were immersed in 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 for 24 hours
at room temperature. The tissues were dehydrated by sequential
washes with 70, 80, 90 and 100% ethanol and embedded in
paraffin. Transversal sections (5 mm) were cut starting from base
area of the heart at intervals of 40 mm and stained with
hematoxylin-eosin for cell morphometry. Tissue sections (2 for
each animal) were examined with Axioplan 2 Zeiss microscope,
and analyzed with ImageJ software. Only digitized images of
cardiomyocytes cut longitudinally with nuclei and cellular limits
visible were used for analysis (an average of 40 cardiomyocytes for
each animal). The diameter of each myocyte was measured across
the region corresponding to the nucleus.
Western blot
40–60 mg of protein were separated by SDS-PAGE 10% gels.
Antibodies and their sources are as follows: anti-SERCA2 (1:1000
ABR), and anti-GAPDH (1:4000 Santa Cruz Biotechnology).
Immunodetection was carried out using enhanced chemilumines-
cence (Amersham Biosciences). Protein levels were expressed as a
ratio of optical densities. GAPDH was used as a control for any
variations in protein loading.
Statistical analysis
All data are expressed as means 6 SEM, and the number of
cells or experiments is shown as n. Significant differences between
groups were determined with a Student’s t-test or ANOVA
followed by the Newman-Keuls post hoc test. Values of p,0.05
were considered to be statistically significant.
Results
Cholinergic signaling in the heart depends on the parasympa-
thetic nervous system as well as on the recently described
cardiomyocyte cholinergic machinery [14], [15], [16]. Firstly, we
assessed whether cholinergic activity at the parasympathetic nerve
endings was modulated in rats with increased sympathetic drive.
To assess the activity of the cardiac autonomic nervous system, we
monitored changes in heart rate (HR) under the inhibition of
parasympathetic and/or sympathetic nervous tone in control and
isoproterenol (ISO)-treated rats. Fig. 1 shows HR responses to
intravenous injections of methylatropine and propranolol used to
calculate the cardiac sympathetic and vagal tone. As shown in
Fig. 1A, ISO administration to rats for seven days produces an
autonomic imbalance characterized by increased cardiac sympa-
thetic tone when compared with control group (p,0.05). In
contrast, cardiac vagal tone tended to be lower in ISO rats when
compared to control (Fig. 1B). When cholinergic signaling was
increased by administration of the cholinesterase inhibitor
pyridostigmine to rats opposite results were observed. Pyridostig-
mine-treated rats displayed reduced sympathetic and increased
parasympathetic tone, respectively. In order to assess the
consequences of increased cholinergic function to the diseased
heart we treated rats simultaneously with ISO and pyridostigmine.
Two distinct doses of pyridostigmine were used in this study
(0.2 mg/kg body weight or 0.5 mg/kg body weight), as shown in
Fig. 1A–B. Pyridostigmine administration to ISO rats prevented
changes in parasympathetic and sympathetic tone, with significant
results observed at the higher dose. Altogether, our data show that
both ISO and pyridostigmine are capable of modulating cardiac
sympathetic and parasympathetic tone in opposite ways, and that
increased ACh availability induced by pyridostigmine administra-
tion to rats is capable of overcoming isoproterenol induced
changes in autonomic function.
To investigate whether the non-neuronal cardiomyocyte cho-
linergic machinery is modulated in vivo in ISO rats, we isolated
ventricular myocytes and investigated expression levels of cholin-
ergic components. mRNA levels of VAChT, ChAT and M2
muscarinic receptors were upregulated in cardiac cells isolated
from ISO-treated rats (Fig. 2A–C). In contrast, lower levels of
Cholinergic Regulation of the Heart
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VAChT, ChAT and M2 mRNA were found in rats with increased
ACh availability due to cholinesterase inhibition. As shown in
Fig. 2A–C, both doses of pyridostigmine used in this study were
efficient in preventing the upregulation of the cholinergic
machinery induced by isoproterenol. Taken together, these data
indicate that reprogramming of cardiomyocyte cholinergic
machinery is under opposing modulation by isoproterenol and
pyridostigmine. Moreover, our finding that cardiomyocyte cho-
linergic proteins are modulated in vivo is potentially important
since it suggests that this intrinsic ACh synthesis site can be
activated directly in the ventricles under hyperadrenergic condi-
tions, and this occurs in parallel with a reduction in parasympa-
thetic tone. In order to extend these findings and to better
understand under what conditions this intrinsic cholinergic system
is modulated, we next performed studies in isolated cardiac cells
and assessed the expression levels of VAChT mRNA in response
to increased adrenergic and cholinergic stimulation. In order to
deplete endogenous acetylcholinesterase and simulate conditions
of increased cholinergic signaling in rat cardiomyocytes, we used
specific siRNA targeting AChE. In rat cardiomyocytes, VAChT
mRNA was upregulated by isoproterenol, while cells treated with
an AChE-siRNA presented significantly decreased VAChT
mRNA levels (Fig.S1). Importantly, AChE silencing partially
abolished the effect of isoproterenol on VAChT expression levels.
Thus these data further support our in vivo findings and confirm
the hypothesis that non-neuronal cholinergic signaling is under
differential modulation by adrenergic and cholinergic signals.
We also assessed expression levels of b1-adrenergic receptor in
ventricular myocytes from ISO and pyridostigmine-treated rats.
As shown in Fig. 2D, 7-day ISO injection to rats led to a significant
b1-adrenergic receptor downregulation. In contrast, ventricular
myocytes from pyridostigmine treated rats presented a robust
increase in b1-AR transcript levels. Administration of pyridostig-
mine to ISO-rats attenuated the ISO-induced-b1-AR downregu-
lation. Collectively, our data from Fig. 2 suggest that cholinergic
signaling is activated in ventricular myocytes under conditions of
increased adrenergic drive, while expression of b1 receptors is
downregulated. Interestingly, both effects were prevented when
ACh availability was increased upon pyridostigmine treatment.
To investigate the functional consequences of these changes in
cholinergic signaling for the heart, we performed morphometric
and echocardiographic analyses. Morphometric analyses of fiber
diameter revealed a significant increase in cardiomyocyte hyper-
trophy in ISO rats (Fig. 3A–B). Pyridostigmine alone, had no effect
on cardiomyocyte size (data not shown), but when combined with
isoproterenol the drug was capable of preventing ISO-induced
Figure 1. Cholinesterase inhibition alters the activity of the
cardiac autonomic system evoked by isoproterenol. Changes in
heart rate (HR) under the inhibition of parasympathetic and/or
sympathetic nervous system were monitored in rats injected with
methylatropine and propranolol for further calculation of sympathetic
and vagal tone, as described in Methods. Two different doses of
pyridostigmine were combined with isoproterenol in this study
(0.2 mg/kg body weight or 0.5 mg/kg body weight). A–B. ISO
administration to rats for seven days resulted in increased sympathetic
tone when compared with control group. Vagal tone was lower in
isoproterenol treated rats when compared to control rats. The higher
dose of pyridostigmine was more efficient in preventing the
isoproterenol-induced changes in heart rate. Rats treated with
pyridostigmine alone (0.5 mg/kg body weight) presented reduced
sympathetic and increased parasympathetic tone, respectively.
n = number of rats. *p,0.05 when compared to control group and
#p,0.05 when compared to the ISO-treated rat using Student’s t test.
doi:10.1371/journal.pone.0100179.g001
Figure 2. Opposite modulation of cardiomyocyte cholinergic
machinery by isoproterenol and pyridostigmine. A–C. qPCR
experiments show that cardiomyocytes from ISO-rats present upregula-
tion of VAChT, ChAT and M2 muscarinic receptor mRNA levels.
Cholinesterase inhibition prevented these effects. Lower levels of
VAChT, ChAT and M2 ACh muscarinic receptor transcripts were
observed in cardiomyocytes from pyridostigmine treated rats. D.
Downregulation of b1-AR transcript is observed in ventricular myocytes
from ISO-rats, while pyridostigmine-treated rats presented opposite
results. Cholinesterase therapy partially reversed the effect of ISO on b1-
AR transcripts. n = 4–6 cardiomyocyte preparations from each group.
*p,0.05 when compared to control group and #p,0.05 when
compared to the ISO-treated rat.
doi:10.1371/journal.pone.0100179.g002
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hypertrophy. Since the higher pyridostigmine dose was more
effective in preventing autonomic imbalance and cardiomyocyte
hypertrophy, we performed all the remaining experiments in ISO
rats treated with the higher dose of pyridostigmine. Real-time
experiments supported the morphometry data since transcript
levels of hypertrophic markers atrial natriuretic peptide (ANP) and
b-myosin heavy chain (b-MHC) were upregulated in cardiomy-
ocytes from ISO-rats (Fig. 4A), an effect that was attenuated in
cardiomyocytes from ISO-rats treated concomitantly with pyrido-
stigmine. Interestingly, pyridostigmine treatment alone significant-
ly decreased fetal gene expression when compared to control.
Table 1 shows that after seven days of ISO administration to rats
there was a significant increase in ejection fraction (EF) and
fractional shortening (FS) indicating that at this stage ventricular
function was still preserved. Interestingly, concomitant treatment
with pyridostigmine produced a similar increase in EF and FS. In
spite of enhanced ejection fraction, pronounced cardiac remod-
eling was observed in ISO-rats. As shown in Table 1, ISO
injection led to significant thickening of the left ventricular
posterior wall and septum both in systole and diastole with most
of these changes significantly attenuated by pyridostigmine. In
addition, the left ventricular internal dimension at diastole was
significantly reduced in ISO-rats. This alteration was accompanied
by a decrease in end-diastolic volume. As shown in Table 1, both
changes were prevented by pyridostigmine. Except for an increase
in chamber dimension at diastole, pyridostigmine treatment had
no effect on cardiac parameters. Thus, these functional data
clearly indicate that increased cholinergic signaling induced by
cholinesterase inhibition significantly attenuated isoproterenol-
induced pathological remodeling.
To further assess the consequences of cholinergic signaling
activation by pyridostigmine in the diseased heart we used the
Langendorff-isolated heart preparation. As shown in Fig. 4B, a
marked decrease in systolic tension was observed in hearts from
the ISO group. This finding contrasted with echocardiography
data where heart function was increased, indicating that in vivo
compensatory mechanisms were contributing to preserve cardiac
function in ISO rats. Combined administration of ISO and
pyridostigmine resulted in significant improvement of cardiac
systolic tension when compared to hearts from ISO-rats.
Pyridostigmine, alone had no effect on systolic tension (data not
shown). To further investigate the underlying cellular basis for the
effects of pyridostigmine on ISO-injected rats, we examined
intracellular Ca2+ in freshly isolated Fluo-4AM loaded ventricular
myocytes. Figure 4C shows representative profiles of intracellular
Ca2+ transient recorded in Fluo-4AM loaded ventricular myo-
cytes. As shown in Figure 4D, ventricular myocytes from ISO rats
present a significant reduction of the peak calcium transient (p,
0.05). The impaired Ca2+ handling observed in cells from ISO rats
corroborates data obtained by the Langendorff technique. In
contrast, the amplitude of the [Ca2+]i transient in cardiomyocytes
from rats treated with a combination of pyridostigmine and ISO
was not statistically different from that obtained in control
cardiomyocytes. The reduced amplitude of the [Ca2+]i transient
in ISO-cardiomyocytes is consistent with the decreased expression
of the sarcoplasmic reticulum Ca2+ pump (SERCA2), therefore we
examined SERCA2 levels in these hearts. As shown in Fig. 4E,
SERCA2 expression levels were significantly reduced in cardio-
myocytes from ISO-treated rats relative to controls. In contrast,
cardiomyocytes from rats treated with a combination of pyrido-
stigmine and ISO, presented normal levels of SERCA2.
Since pyridostigmine administration prevented the ISO-in-
duced b-1 receptor downregulation, we addressed the functionality
of these receptors by assessing the percentage increase in Ca2+
transient amplitude upon ISO stimulation. Upon reaching steady
state in our normal Tyrode control solution, perfusion of myocytes
with a sub-maximal dose of ISO (50 nmol/L) produced a large
increase in Ca2+ transient amplitude in cells from control rats. This
effect is shown in Fig. 4F, which shows the % D in response to
ISO. As expected, perfusion with ISO had a less pronounced effect
on the Ca2+ transient amplitude in myocytes from ISO-rats,
indicating impaired b-adrenergic responsiveness of cells from this
group. In contrast, cardiomyocytes from rats treated with a
combination of ISO and pyridostigmine presented normal
response to ISO stimulation, comparable to that observed in cells
from control rats. Thus, pyridostigmine treatment restores the
functionality of b-adrenergic receptors in ISO-myocytes corrob-
orating our real time PCR data. Taking together, our data show
that increased cholinergic signaling induced by pyridostigmine is
capable of preventing deleterious effects of increased sympathetic
drive.
To investigate whether increased cholinergic signaling would
also revert pre-existing sympathetic hyperactivity-induced heart
failure, we treated a2A/a2C-KO mice with pyridostigmine. Mice
lacking both a2A-and a2C- adrenergic receptors (a2A/a2C-KO)
develop sympathetic hyperactivity-induced heart failure [19], [29].
The first signs of heart failure are observed at age of 5 months.
Fig. 5A–B shows that a2A/a2C-KO mice present reduced left
ventricular ejection fraction and fractional shortening as assessed
by echocardiography, and administration of pyridostigmine for 28
days significantly increased these parameters towards control
levels. These data confirm our previous finding that baseline
fractional shortening was significantly reduced in a2A/a2C-KO
mice, when compared with control mice [19]. To further assess
directly the heart dysfunction in a2A/a2C–KO mice we used the
Langendorff-isolated heart preparation. In agreement with the
Figure 3. Cholinesterase inhibition prevents isoproterenol
induced-hypertrophy. A. Representative images. B. Morphometry
analyses showing the increase in fiber diameter in rats subjected to
seven day ISO administration. Cholinesterase inhibition prevented the
ISO-induced cardiomyocyte hyperthophy. n = number of hearts ana-
lysed. *p,0.05 when compared to other groups. Scale bar = 10 mm.
doi:10.1371/journal.pone.0100179.g003
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results obtained with echocardiography studies, isolated hearts
from a2A/a2C–KO mice had significantly decreased systolic
tension when compared to WT hearts (Fig. 5C). Pyridostigmine
treatment reversed the decreased systolic tension observed in a2A/
a2C–KO hearts. Similarly, a contractile dysfunction was observed
in freshly isolated adult ventricular myocytes from a2A/a2C-KO
mice, which demonstrated reduced fractional shortening when
compared to cardiomyocytes from WT mice (Fig. 5D). Cholines-
terase inhibition of a2A/a2C-KO mice reversed this change thus
confirming that increased cholinergic signaling protects against
chronic adrenergic stimulation.
Discussion
Here, we show that both cholinergic axes, the cardiac
parasympathetic system and non-neuronal cardiomyocyte cholin-
ergic machinery are modulated in opposite directions under
conditions of increased sympathetic drive or of increased ACh
availability. As such, in a model of increased adrenergic
stimulation, parasympathetic tone is reduced while a significant
induction of VAChT, ChAT and M2-receptors is observed in
ventricular myocytes, thus uncovering a new site of ACh synthesis
in the ventricles in vivo. When ACh availability increases, for
example by administration of pyridostigmine, this effect is
suppressed. In the presence of pyridostigmine, normal parasym-
pathetic response is restored and pathological remodeling induced
by increased sympathetic drive is prevented. Thus, our findings
indicate that therapies aimed at enhancing cholinergic activity
might be an important target in heart failure.
Modulation of cardiomyocyte cholinergic machinery
in vivo
We have previously shown that ventricular myocytes express
cholinergic components ChAT, VAChT, CHT1 and muscarinic
receptor type 2 and release ACh [16], [17]. Here, we show that
this intrinsic cholinergic machinery is upregulated in vivo and
in vitro by isoproterenol, suggesting that under this condition ACh
release by cardiomyocytes is increased. These data corroborate
our previous finding that isoproterenol treatment in vitro leads to a
significant increase in expression levels of cholinergic components
in neonatal cardiomyocytes [16]. A possibility raised by these
findings is that ACh released by cardiomyocytes acts as a feedback
signal to counteract excessive adrenergic stimulation thus exerting
protective effects. Evidence supporting this hypothesis comes from
the fact that when ACh synthesis by cardiomyocytes is blocked, for
example in vesamicol treated myocytes isoproterenol treatment
leads to a greater increase in cell surface area when compared with
cells treated with isoproterenol alone [16]. Therefore, in the
absence of VAChT the extent of cardiac hypertrophy induced by
isoproterenol is increased corroborating the fact that cardiomyo-
cyte cholinergic machinery exerts protective effects. In addition,
mice with targeted deletion of VAChT in cardiomyocytes present
cardiac dysfunction, increased ROS levels, and cardiomyocyte
hypertrophy [17]. Similar findings were also observed in another
genetic mouse model with ablation of ChAT (the enzyme
responsible for ACh synthesis) in cardiomyocytes [17]. Along
these lines, Kakinuma et al. have demonstrated that increased
expression of ChAT in cardiomyocytes turns the heart more
resistant to injury caused by ischemia and reperfusion [30]. Taking
all these into consideration, it appears that under stress conditions
the cardiomyocyte cholinergic machinery is activated and this may
contribute to cardiac protection. When ACh availability is
restored, for example during cholinesterase therapy, upregulation
of cardiomyocyte cholinergic machinery is no longer required.
This assumption is further supported by our finding that
pyridostigmine administration in vivo leads to a significant reduc-
tion in VAChT, ChAT, and M2 expression, and by our in vitro
data showing that cardiomyocytes transfected with AChE siRNA
Table 1. Echocardiographic parameters.
Parameter CT (n =8) ISO (n=8) ISO+PYR (n=9) PYR (n=4)
Cardiac output (mL/min) 65.0963.03 48.7466.11* 71.2262.31& 76.6463.84&
LV internal dimension (diastole,
mm)
6.8760.18 5.9260.18* 6.8360.15& 7.6360.22*& #
LV internal dimension (systole,
mm)
4.0860.10 3.2460.20* 3.48660.13* 4.2860.39&#
LV posterior wall (systole, mm) 2.2960.08 3.2760.19* 2.8560.15* 2.6060.17&
LV posterior wall (diastole, mm) 1.4360.05 2.1960.14* 1.8160.10& 1.5460.17&
interventricular septal dimension
(systole, mm)
1.9060.10 2.6760.13* 2.3660.07*& 1.9060.13&#
interventricular septal dimension
(diastole, mm)
1.0560.04 1.5760.07* 1.2960.04*& 1.1860.06&
LV ejection fraction (%) 72.2161.74 78.9461.28* 79.161.73* 73.7263.32
LV fractional shortening (%) 41.361.73 47.561.31* 51.061.57* 44.3462.97
LV systolic volume (mL) 178.268.98 134.2615.92* 200.065.33& 215.8613.73&
End diastolic LV volume (mL) 246.269.12 169.9619.35* 253.064.85& 293.8619.06&
End systolic LV volume (mL) 68.0464.37 35.6364.15* 52.9864.58*& 77.97611.69&#
Heart rate (bpm) 367.0611.11 361.565.79 356.468.61 356.165.56
Echocardiographic measurements of cardiac parameters in rats following isoproterenol injection for 7 days. Pyridostigmine treatment of ISO-rats attenuated the
development of cardiac remodeling induced by isoproterenol. n = number of rats analysed in each experimental group.
* = p,0.05 versus CT,
& = p,0.05 versus ISO,
#= p,0.05 versus ISO+PYR.
doi:10.1371/journal.pone.0100179.t001
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Figure 4. Increased cholinergic signaling functionally prevents ISO-induced pathological remodeling. A. Differential effects of
isoproterenol and pyridostigmine on transcripts for ANP and b-MHC were detected by real-time PCR in cardiomyocytes from each experimental
group. Administration of pyridostigmine prevents the upregulation of hypertrophic markers in cardiomyocytes from ISO-rats. n = 4–6 cardiomyocyte
preparations from each group. *p,0.05 when compared to control group and #p,0.05 when compared to the ISO-treated rat. B. Pyridostigmine
treatment restored systolic tension in ISO-treated rats back to control levels. n = 7 hearts per group. C. Representative profile of the Ca2+ transient. D.
Bar graph shows averaged-peak Ca2+ transient. Significant reduction in peak Ca2+ transient is observed in cardiomyocytes from ISO-rats.
Anticholinesterase therapy significantly prevented intracellular Ca2+ dysfunction in cardiomyocytes from ISO-rats. n = number of ventricular myocytes
analysed. E. Top, representative western-blot. Bottom, averaged-densitometry. Pyridostigmine-treatment prevents SERCA2 downregulation in ISO
cardiomyocytes. F. % Increase in cytosolic Ca2+ concentration ([Ca2+]i) above basal level measured 2 minutes after stimulation with 50nmol/L
isoproterenol. b-adrenergic stimulation increased Ca2+ transient amplitude in cardiomyocyters from saline-treated group more than in cells from ISO-
rats. Cardiomyocytes from ISO/PYR rats presented a similar increase in [Ca2+]i transient amplitude in response to acute ISO perfusion as control cells.
* = p,0.05 when compared to other experimental groups. n = number of cells analysed from 4 different animals in each group.
doi:10.1371/journal.pone.0100179.g004
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present significant reduction in VAChT mRNA. It is worth noting
the fact that this cardiomyocyte intrinsic cholinergic machinery is
subjected to opposing modulation by isoproterenol and pyrido-
stigmine, suggesting that cardiac cells may represent another level
of cholinergic control of heart function, that goes beyond the
parasympathetic autonomic system.
Cardioprotective effects of cholinesterase inhibition
The present results with pyridostigmine are consistent with the
idea that enhancing ACh signaling may limit adverse remodeling
and cardiac deterioration by controlling cardiac gene expression,
preventing cardiomyocyte hypertrophy, and therefore preserving
Ca2+ cycling and contractile function. Taken together, these
results provide the cellular basis to attempt to improve cholinergic
neurotransmission and restore parasympathetic-sympathetic bal-
ance to influence the outcome of heart failure in clinical settings.
Previous data in the literature have shown that treatment with
pyridostigmine improves cardiocirculatory parameters in rats with
chronic heart failure due to coronary artery ligation [31], [32].
Here, we extended these findings by showing the mechanisms
involved in the protective effects of cholinesterase inhibition
therapy. Accordingly, pyridostigmine improves cardiac function
by preventing the increase in sympathetic activity, hypertrophic
growth, and by improving calcium dynamics. The signaling
pathways mediating these effects, however, have yet to be
elucidated. In addition, we found that pyridostigmine can reverse
pre-existing pathological remodeling in a model of hyperadrener-
gic induced heart failure, indicating that increased ACh availabil-
ity is associated to cardioprotection. Overall, these findings are
consistent with a recent study using a cohort of 7073 subjects
showing that the use of cholinesterase inhibitor was associated with
a reduced risk of myocardial infarction and death [13].
Importantly, beneficial effects of cholinesterase inhibition are
not restricted to the synaptic cleft but also observed locally in
ventricular myocytes. Ventricular myocytes are known to express
AChE [16], and its inhibition leads to a local increase in
cardiomyocyte derived-ACh [17]. In cardiac cells, ACh acting
through M2 receptors activates nitric oxide synthesis exerting anti-
hypertrophic effects [16]. In addition, we have demonstrated that
neonatal rat cardiomyocytes transfected with siRNA directed to
AChE presented reduced expression levels of ANP and b-MHC,
and were protected from hypertrophic effects of isoproterenol
[16].
Taking together, our data suggest that the cardiomyocyte
cholinergic machinery plays a role as an adaptative defense
mechanism activated under conditions of increased sympathetic
drive. Increased cholinergic tone induced by pyridostigmine is
important to restore the balance of the autonomic nervous system
and prevent cardiovascular dysfunction in two models of
sympathetic hyperactivity. Overall our data support the fact that
therapies aimed at enhancing cholinergic signaling in the synaptic
cleft and locally in the heart might be an important target in heart
failure.
Supporting Information
Figure S1 Adrenergic and cholinergic signals regulate
VAChT mRNA levels in neonatal cardiomyocytes. siRNA
targeting AChE significantly reduces mRNA expression levels of
VAChT. Isoproterenol treatment significantly increases VAChT
mRNA levels in neonatal cardiomyocytes, an effect that is
significantly attenuated in cells transfected with siRNA targeting
AChE. n= 4 samples from each group. *p,0.05 when compared
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